Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine

This publication has 27 references indexed in Scilit:

• Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis.
  Gut, 1995
• Insulin‐like growth factors counteract the effect of interleukin 1β on type II phospholipase A2 expression and arachidonic acid release by rabbit articular chondrocytes
  FEBS Letters, 1994
• Sulfasalazine in early rheumatoid arthritis. A 48‐week double‐blind, prospective, placebo‐controlled study
  Arthritis & Rheumatism, 1993
• Purification and characterization of a phospholipase A2 from human ileal mucosa
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
• Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication
  Critical Care Medicine, 1993
• Sulphasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds.
  Annals of the Rheumatic Diseases, 1992
• Initiation of Anastomotic Recurrence of Crohn's Disease after Ileocolic Resection: Onset Proximal to the Junction and Preceded by Increased Phospholipase A₂Activity
  Scandinavian Journal of Gastroenterology, 1992
• Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action
  Immunology Letters, 1991
• Interleukin-1β, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells
  Biochemical and Biophysical Research Communications, 1991
• Pathogenesis of hypotension in septic shock
  Critical Care Medicine, 1988